BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026

Friday, June 12, 2026 1 min read

Key Takeaway: BeOne Medicines is highlighting its hematology franchise at EHA 2026, focusing on B-cell cancer innovation. The event aims to showcase advancements in treatment options and research. Details about specific innovations or data were not provided in the article.